Search Within

Gopakumar Vasudeva Iyer

Formats
  1. Meeting Abstract (205)
  2. Journal Article (121)
  3. Review (11)
  4. Book Section (5)
  5. Editorial (3)
  6. Correspondence (2)
  7. Research Letter (1)
Groups
  1. Department of Medicine (348)
  2. Genitourinary Oncology Service (348)
  3. Solid Tumor Oncology Division (348)
  4. Department of Pathology and Laboratory Medicine (215)
  5. GSK Faculty (195)
  6. Human Oncology and Pathogenesis Program (192)

More Groups

People
  1. David Solit (182)
  2. Hikmat Al-Ahmadie (182)
  3. Jonathan Rosenberg (173)
  4. Dean Bajorin (163)
  5. Bernard Bochner (129)
  6. Michael Berger (102)

More People

Years
  1. 2025 (20)
  2. 2024 (41)
  3. 2023 (30)
  4. 2022 (33)
  5. 2021 (34)
  6. 2020 (22)

More Years

Publications
  1. Journal of Clinical Oncology (120)
  2. Laboratory Investigation (27)
  3. Modern Pathology (20)
  4. Cancer Research (17)
  5. Clinical Cancer Research (14)
  6. Annals of Oncology (13)

More Publications

Publishers
  1. American Society of Clinical Oncology (129)
  2. Nature Publishing Group (43)
  3. American Association for Cancer Research (34)
  4. Elsevier Inc. (33)
  5. Nature Research (20)
  6. Oxford University Press (15)

More Publishers

Results (348)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cutaneous toxicity and clinical outcomes with enfortumab vedotin and pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma
    Meeting Abstract

    Arbuiso, A.; Sternschuss, M.; Whiting, K.; Gupta, A.; Huttenlocher Bent, E.; Alvarez, N.; Regazzi, A. M.; Liang, S.; Ahmed, F.; Akin, O.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Treatment patterns and clinical outcomes with platinum-based chemotherapy after enfortumab vedotin and pembrolizumab in patients with metastatic urothelial carcinoma
    Meeting Abstract

    Sternschuss, M.; Whiting, K.; Arbuiso, A.; Gupta, A.; Bent, E. H.; Alvarez, N.; Regazzi, A. M.; Liang, S.; Ahmed, F.; Akin, O.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • EV-302: Long-term subgroup analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC)
    Meeting Abstract

    Bedke, J.; Powles, T.; Valderrama, B. P.; Gupta, S.; Kikuchi, E.; Loriot, Y.; Galsky, M D.; Sridhar, S. S.; Yu, E. Y.; Hoffman-Censits, J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Quality of informed consent via telemedicine compared with in-person for clinical cancer research
    Journal Article

    Sternschuss, M.; Lattanzi, M.; Vertosick, E.; Austria, M.; Martin, S.; Regazzi, A.; Buckely, M. T.; Lengfellner, J.; Riely, G. J.; Solit, D. B.; more...
    JCO Oncology Practice (2025)

    Fulltext@MSK | Save
  • Nonoperative management of mismatch repair-deficient tumors
    Journal Article

    Cercek, A.; Foote, M. B.; Rousseau, B.; Smith, J. J.; Shia, J.; Sinopoli, J.; Weiss, J.; Lumish, M.; Temple, L.; Patel, M.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma
    Journal Article

    Sternschuss, M.; Toumbacaris, N.; Das, J. P.; Powles, T.; Kotecha, R. R.; Laccetti, A. L.; Xiao, H.; Feld, E.; McHugh, D. J.; Keegan, N. M.; more...
    ESMO Open (2025)

    Fulltext@MSK | Save
  • NEXUS-01, a phase 1 study of LY4052031, an antibody-drug conjugate targeting Nectin-4 in participants with advanced or metastatic urothelial carcinoma or other solid tumors
    Meeting Abstract

    Gao, X.; Patnaik, A.; Lakhani, N. J.; Call, J. A.; Galsky, M. D.; Garmezy, B.; Wei, A. Z.; Carter, L.; Powles, T.; Siefker-Radtke, A. O.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301)
    Meeting Abstract

    Hansen, A. R.; Zhang, A. Y.; Boni, V.; Mantia, C.; Yu, E. Y.; Weickhardt, A. J.; Robert, M.; Gupta, S.; Morales-Barrera, R.; Hoimes, C. J.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC)
    Meeting Abstract

    Powles, T.; Van Der Heijden, M. S.; Loriot, Y.; Bedke, J.; Valderrama, B. P.; Iyer, G.; Kikuchi, E.; Hoffman-Censits, J.; Vulsteke, C.; Drakaki, A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1
    Meeting Abstract

    Iyer, G.; Ebi, H.; Cook, N.; Gao, X.; Kitano, S.; Matsubara, N.; Reimers, M. A.; Siefker-Radtke, A. O.; Kim, M.; Galsky, M. D.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save